Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004136 · ClinicalTrials.gov registry record · Phase 2
Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
A Phase 2 study of Metastatic Cancer and Liver Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT00004136: Completed Phase 2 study of Metastatic Cancer and Liver Cancer, sponsored by M.D. Anderson Cancer Center.
NCT00004136 is a Phase 2 study of Metastatic Cancer and Liver Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 59 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004136, a Phase 2 study of Metastatic Cancer and Liver Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Heating tumors to several degrees above body temperature may kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of heat therapy in treating patients who have unresectable primary or metastatic liver cancer.
Conditions Studied
Interventions
- PROCEDURE Radiofrequency Ablation
Study Locations (1)
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 1998-03-09 |
| Est. Completion | 2006-01-25 |
| Phase | Phase 2 |
What the finished NCT00004136 record still lists
NCT00004136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency Ablation is the first listed.
NCT00004136 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00004136 about?
NCT00004136 is a clinical study titled "Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer". RATIONALE: Heating tumors to several degrees above body temperature may kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of heat therapy in treating patients who have unresectable primary or metastatic liver cancer.
What is the current status of trial NCT00004136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 1998-03-09. Estimated completion is 2006-01-25.
What conditions does trial NCT00004136 study?
This clinical trial studies the following conditions: Metastatic Cancer, Liver Cancer.
What interventions are being tested in trial NCT00004136?
The interventions under investigation include: Radiofrequency Ablation (PROCEDURE).
Who is sponsoring clinical trial NCT00004136?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004136 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00004136's enrollment target sits among peer trials
59 52nd of 109 higher than 57 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI